PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : C07D 405/06, A61K 31/445, C07D 405/12, 405/14, 413/14, 493/04 — A1

(11) International Publication Number: WO 98/29411

(43) International Publication Date: 9 July 1998 (09.07.98)

(21) International Application Number: PCT/EP97/07034

(22) International Filing Date: 15 December 1997 (15.12.97)

(30) Priority Data:
9627006.1 27 December 1996 (27.12.96) GB

(71) Applicant (*for all designated States except US*): KNOLL AKTIENGESELLSCHAFT [DE/DE]; Knollstrasse, D–67061 Ludwigshafen (DE).

(72) Inventors; and


(75) Inventors/Applicants (*for US only*): WISHART, Neil [GB/GB]; R5 Pennyfoot Street, Nottingham, Nottinghamshire NG1 1GF (GB). BIRCH, Alan, Martin [GB/GB]; R5 Pennyfoot Street, Nottingham, Nottinghamshire NG1 1GF (GB).

(74) Agent: MILLER, Thomas, Kerr; BASF Aktiengesellschaft, D–67056 Ludwigshafen (DE).

(81) Designated States: AL, AU, BG, BR, BY, CA, CN, CZ, GE, HU, ID, IL, JP, KR, KZ, LT, LV, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TR, UA, US, Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).

Published
With international search report.

(54) Title: SULFONAMIDE COMPOUNDS HAVING 5–HT RECEPTOR ACTIVITY



(I)

(57) Abstract

Compounds of formula (I) and pharmaceutically acceptable salts thereof in which A is methylene or –O–; B is methylene or –O–; g is 0, 1, 2, 3 or 4; U is an alkylene chain optionally substituted by one or more alkyl; Q represents a divalent group containing nitrogen atoms; and T represents an aryl or heteroaryl group, have utility in the treatment of central nervous system disorders, for example depression, anxiety, psychoses (for example schizophrenia), tardive dyskinesia, Parkinson's disease, obesity, hypertension, Tourette's syndrome, sexual dysfunction, drug addiction, drug abuse, cognitive disorders, Alzheimer's disease, senile dementia, obsessive–compulsive behaviour, panic attacks, social phobias, eating disorders and anorexia, cardiovascular and cerebrovascular disorders, non–insulin dependent diabetes mellitus, hyperglycaemia, constipation, arrhythmia, disorders of the neuroendocrine system, stress and spasticity.